Abeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on ABEO. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Trading Down 0.7 %

Abeona Therapeutics stock opened at $5.94 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01. The stock has a market cap of $258.21 million, a P/E ratio of -2.21 and a beta of 1.52. The firm’s fifty day moving average price is $6.20 and its 200-day moving average price is $5.29.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 2,434 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Abeona Therapeutics in the 1st quarter worth approximately $91,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics during the 3rd quarter valued at $84,000. Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics during the 3rd quarter valued at $151,000. Finally, XTX Topco Ltd purchased a new position in Abeona Therapeutics in the 3rd quarter worth $160,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.